| First Author | Carter DR | Year | 2015 |
| Journal | Sci Transl Med | Volume | 7 |
| Issue | 312 | Pages | 312ra176 |
| PubMed ID | 26537256 | Mgi Jnum | J:234050 |
| Mgi Id | MGI:5788827 | Doi | 10.1126/scitranslmed.aab1803 |
| Citation | Carter DR, et al. (2015) Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 7(312):312ra176 |
| abstractText | Amplification of the MYCN oncogene predicts treatment resistance in childhood neuroblastoma. We used a MYC target gene signature that predicts poor neuroblastoma prognosis to identify the histone chaperone FACT (facilitates chromatin transcription) as a crucial mediator of the MYC signal and a therapeutic target in the disease. FACT and MYCN expression created a forward feedback loop in neuroblastoma cells that was essential for maintaining mutual high expression. FACT inhibition by the small-molecule curaxin compound CBL0137 markedly reduced tumor initiation and progression in vivo. CBL0137 exhibited strong synergy with standard chemotherapy by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells and suggesting a treatment strategy for MYCN-driven neuroblastoma. |
